- Home
- CNSP vs APVO Comparison
CNSP vs APVO Comparison
Compare CNSP & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- APVO
- Stock Information
- Founded
- CNSP 2017
- APVO 2016
- Country
- CNSP United States
- APVO United States
- Employees
- CNSP N/A
- APVO N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- CNSP Health Care
- APVO Health Care
- Exchange
- CNSP Nasdaq
- APVO Nasdaq
- Market Cap
- CNSP 6.5M
- APVO 5.4M
- IPO Year
- CNSP 2019
- APVO N/A
- Fundamental
- Price
- CNSP $3.23
- APVO $3.47
- Analyst Decision
- CNSP Strong Buy
- APVO Strong Buy
- Analyst Count
- CNSP 1
- APVO 1
- Target Price
- CNSP $0.50
- APVO $296.00
- AVG Volume (30 Days)
- CNSP 941.1K
- APVO 44.0K
- Earning Date
- CNSP 03-31-2025
- APVO 03-04-2025
- Dividend Yield
- CNSP N/A
- APVO N/A
- EPS Growth
- CNSP N/A
- APVO N/A
- EPS
- CNSP N/A
- APVO N/A
- Revenue
- CNSP N/A
- APVO N/A
- Revenue This Year
- CNSP N/A
- APVO N/A
- Revenue Next Year
- CNSP N/A
- APVO N/A
- P/E Ratio
- CNSP N/A
- APVO N/A
- Revenue Growth
- CNSP N/A
- APVO N/A
- 52 Week Low
- CNSP $2.81
- APVO $3.01
- 52 Week High
- CNSP $1,195.00
- APVO $399.60
- Technical
- Relative Strength Index (RSI)
- CNSP 35.22
- APVO 33.42
- Support Level
- CNSP $4.60
- APVO $3.20
- Resistance Level
- CNSP $9.50
- APVO $3.65
- Average True Range (ATR)
- CNSP 0.94
- APVO 0.34
- MACD
- CNSP -0.15
- APVO 0.01
- Stochastic Oscillator
- CNSP 6.28
- APVO 31.51
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.